Data from FDA - Curated by EPG Health - Last updated 21 December 2016

Indication(s)

1 INDICATIONS & USAGE Clindamycin phosphate and tretinoin gel 1.2% / 0.025% is indicated for the topical treatment of acne vulgaris in patients 12 years or older. Clindamycin phosphate and tretinoin gel 1.2% / 0.025% is a lincosamide antibiotic and retinoid combination product indicated for the topical treatment of acne vulgaris in patients 12 years or older. (1)

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Acute and Advanced Heart Failure

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

+ 3 more

Allergic Rhinitis

Allergic Rhinitis

Allergic rhinitis causes great strain on the workforce. Help to reduce sick days and improve productivity with appropriate treatment options.

+ 4 more

Anticoagulation Therapy for Stroke Prevention

Anticoagulation Therapy for Stroke Prevention

Anticoagulation therapy for Stroke Prevention Learning Zone offers a deep-dive into atrial fibrillation causes, consequences, diagnosis and management to help you deliver optimal care and prevent strokes in patients living with this common arrhythmia.

Load more

Related Content

Advisory information

contraindications
4 CONTRAINDICATIONS Clindamycin phosphate and tretinoin gel is contraindicated in patients with regional enteritis, ulcerative colitis, or history of antibiotic-associated colitis. Clindamycin phosphate and tretinoin gel is contraindicated in patients with regional enteritis, ulcerative colitis, or history of antibiotic–associated colitis. (4)
Adverse reactions

6 ADVERSE REACTIONS Observed local adverse reactions in patients treated with clindamycin phosphate and tretinoin gel were skin erythema, scaling, itching, burning, and stinging.

Other most commonly reported adverse events (?

1 % in patients treated with clindamycin phosphate and tretinoin gel) were nasopharyngitis, pharyngolaryngeal pain, dry skin, cough, and sinusitis.

(6.1) To report SUSPECTED ADVERSE REACTIONS, contact Actavis at 1-800-432-8534 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

6.1 Clinical Studies Experience Because clinical trials are conducted under prescribed conditions, adverse reaction rates observed in the clinical trial may not reflect the rates observed in practice.

The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse reactions that appear to be related to drug use for approximating rates.

The safety data presented in Table 1 (below) reflects exposure to clindamycin phosphate and tretinoin gel in 1,853 patients with acne vulgaris.

Patients were 12 years and older and were treated once daily for 12 weeks.

Adverse reactions that were reported in?

1 % of patients treated with clindamycin phosphate and tretinoin gel were compared to adverse reactions in patients treated with clindamycin phosphate 1.2 % in vehicle gel, tretinoin 0.025 % in vehicle gel, and the vehicle gel alone: Table 1: Adverse Reactions Reported in at Least 1 % of Patients Treated with Clindamycin Phosphate and Tretinoin Gel: 12-Week Studies Clindamycin Phosphate and Tretinoin Gel Clindamycin Tretinoin Vehicle N=1853 N=1428 N=846 N=423 N (%) N (%) N (%) N (%) Note:

Formulations used in all treatment arms were in the clindamycin phosphate and tretinoin vehicle gel.

PATIENTS WITH AT LEAST ONE AR 497 (27) 342 (24) 225 (27) 91 (22) Nasopharyngitis 65 (4) 64 (5) 16 (2) 5 (1) Pharyngolaryngeal pain 29 (2) 18 (1) 5 (1) 7 (2) Dry skin 23 (1) 7 (1) 3 (<1) 0 (0) Cough 19 (1) 21 (2) 9 (1) 2 (1) Sinusitis 19 (1) 19 (1) 15 (2) 4 (1) Cutaneous safety and tolerance evaluations were conducted at each study visit in all of the clinical trials by assessment of erythema, scaling, itching, burning, and stinging: Table 2: Clindamycin Phosphate and Tretinoin Gel-Treated Patients with Local Skin Reactions Local Reaction Baseline End of Treatment N=1835 N=1614 N (%) N (%) Erythema 636 (35) 416 (26) Scaling 237 (13) 280 (17) Itching 189 (10) 70 (4) Burning 38 (2) 56 (4) Stinging 33 (2) 27 (2) At each study visit, application site reactions on a scale of 0 (none), 1 (mild)

2 (moderate), and 3 (severe), and the mean scores were calculated for each of the local skin reactions.

In Studies 1 and 2, 1277 subjects enrolled with moderate to severe acne, 854 subjects treated with clindamycin phosphate and tretinoin gel and 423 treated with vehicle.

Analysis over the twelve week period demonstrated that cutaneous irritation scores for erythema, scaling, itching, burning, and stinging peaked at two weeks of therapy, and were slightly higher for the clindamycin phosphate and tretinoin-treated group, decreasing thereafter.

One open-label 12-month safety study for clindamycin phosphate and tretinoin gel showed a similar adverse reaction profile as seen in the 12-week studies.

Eighteen out of 442 subjects (4 %) reported gastrointestinal symptoms.

Usage information

Dosing and administration

2 DOSAGE & ADMINISTRATION At bedtime, squeeze a pea-sized amount of medication onto one fingertip, dot onto the chin, cheeks, nose, and forehead, then gently rub over the entire face.

Clindamycin phosphate and tretinoin gel should be kept away from the eyes, the mouth, angles of the nose, and mucous membranes.

Clindamycin phosphate and tretinoin gel is not for oral, ophthalmic, or intravaginal use.

Apply a pea-sized amount to the entire face once daily at bedtime.

Do not apply to eyes, mouth, angles of the nose, or mucous membranes.

(2) Clindamycin phosphate and tretinoin gel is not for oral, ophthalmic, or intravaginal use.

(2)

Use in special populations

8 USE IN SPECIFIC POPULATIONS 8.1 PREGNANCY Pregnancy Category C. There are no well-controlled trials in pregnant women treated with clindamycin phosphate and tretinoin gel.

Clindamycin phosphate and tretinoin gel should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Clindamycin phosphate and tretinoin gel was tested for maternal and developmental toxicity in New Zealand White Rabbits with topical doses of 60, 180 and 600 mg/kg/day.

Clindamycin phosphate and tretinoin gel at 600 mg/kg/day (approximately 12 times the recommended clinical dose assuming 100 % absorption and based on body surface area comparison) was considered to be the no-observed-adverse-effect level (NOAEL) for maternal and developmental toxicity following dermal administration of clindamycin phosphate and tretinoin gel for two weeks prior to artificial insemination and continuing until gestation day 18, inclusive.

For purposes of comparisons of the animal exposure to human exposure, the recommended clinical dose is defined as 1 g of clindamycin phosphate and tretinoin gel applied daily to a 60 kg person.

Clindamycin Teratology (Segment II) studies using clindamycin were performed orally in rats (up to 600 mg/kg/day) and mice (up to 100 mg/kg/day) (583 and 49 times amount of clindamycin in the recommended clinical dose based on a body surface area comparison, respectively) or with subcutaneous doses of clindamycin up to 180 mg/kg/day (175 and 88 times the amount of clindamycin in the recommended clinical dose based on a body surface area comparison, respectively) revealed no evidence of teratogenicity.

Tretinoin In oral Segment III studies in rats with tretinoin, decreased survival of neonates and growth retardation were observed at doses in excess of 2 mg/kg/day (~ 78 times the recommended clinical dose assuming 100 % absorption and based on body surface area comparison).

With widespread use of any drug, a small number of birth defect reports associated temporally with the administration of the drug would be expected by chance alone.

Thirty cases of temporally associated congenital malformations have been reported during two decades of clinical use of another formulation of topical tretinoin.

Although no definite pattern of teratogenicity and no causal association have been established from these cases, 5 of the reports describe the rare birth defect category, holoprosencephaly (defects associated with incomplete midline development of the forebrain).

The significance of these spontaneous reports in terms of risk to the fetus is not known.

Dermal tretinoin has been shown to be fetotoxic in rabbits when administered in doses 40 times the recommended human clinical dose based on a body surface area comparison.

Oral tretinoin has been shown to be fetotoxic in rats when administered in doses 78 times the recommended clinical dose based on a body surface area comparison.

8.3 NURSING MOTHERS It is not known whether clindamycin is excreted in human milk following use of clindamycin phosphate and tretinoin gel.

However, orally and parenterally administered clindamycin has been reported to appear in breast milk.

Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

It is not known whether tretinoin is excreted in human milk.

Because many drugs are excreted in human milk, caution should be exercised when clindamycin phosphate and tretinoin gel is administered to a nursing woman.

8.4 PEDIATRIC USE Safety and effectiveness of clindamycin phosphate and tretinoin gel in pediatric patients under the age of 12 have not been established.

Clinical trials of clindamycin phosphate and tretinoin gel included patients 12 to 17 years of age.

[See Clinical Studies (14)] 8.5 GERIATRIC USE Clinical studies of clindamycin phosphate and tretinoin gel did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

Interactions

7 DRUG INTERACTIONS Concomitant use of topical medications with a strong drying effect can increase skin irritation.

Use with caution.

(7.1) Clindamycin phosphate and tretinoin gel should not be used in combination with erythromycin-containing products because of its clindamycin component.

(7.2) 7.1 Concomitant Topical Medication Concomitant topical medication, medicated or abrasive soaps and cleansers, soaps and cosmetics that have a strong drying effect, and products with high concentrations of alcohol, astringents, spices or lime should be used with caution.

When used with clindamycin phosphate and tretinoin gel, there may be increased skin irritation.

7.2 Erythromycin Clindamycin phosphate and tretinoin gel should not be used in combination with erythromycin-containing products due to its clindamycin component.

In vitro studies have shown antagonism between these two antimicrobials.

The clinical significance of this in_vitro antagonism is not known.

7.3

Neuromuscular Blocking

Agents Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents.

Therefore, clindamycin phosphate and tretinoin gel should be used with caution in patients receiving such agents.

More information

Category Value
Authorisation number ANDA202564
Agency product number 5688UTC01R
Orphan designation No
Product NDC 0472-1790
Date Last Revised 30-09-2015
Type HUMAN PRESCRIPTION DRUG
RXCUI 882548
Marketing authorisation holder Actavis Pharma, Inc.